Video will be live on Monday, July 7 at 1:00 PM Central Time. 

▪️ Join my channel to get access to perks or simply subscribe and turn on your notifications!
▪️ Download my FREE GLP-1/GIP Medication Information Sheet and 7-Day Best Weight Journal here.
▪️ Join my Empowerment Hub and discover sustainable, evidence-based solutions to transform your health and embrace self-care without guilt.

👉 Enjoy lifetime free access to Daily Momentum and Nourish & Thrive, your go-to spaces for daily support, encouragement, and practical tips. Or, become a Core Member for just $15/month or $145/year to unlock expert coaching, exclusive resources, and a proven system that includes live Q&As and monthly toolkits, to help you create real, lasting change.
🔗 https://drdans-empowermenthub.mn.co

–

Semaglutide and PAD: A New Frontier in Mobility Medicine

If you’ve ever felt your legs start to burn or give out while walking, and thought it was just “getting older” or being out of shape, it might actually be something more serious. 

Peripheral Artery Disease, or PAD, is surprisingly common—especially for people with Type 2 diabetes or obesity—and it causes narrowing in the leg arteries that leads to pain and limits mobility. 

In this video, I share exciting news about semaglutide, a medication many know for weight loss and blood sugar control, but that also shows real promise for improving blood flow and walking ability in people with PAD. The STRIDE trial tested semaglutide against placebo for a full year in adults with both PAD and diabetes, showing meaningful improvements in walking distance, pain reduction, and overall quality of life. 

Beyond the numbers, this means everyday tasks like grocery shopping can become easier and less painful. I also talk about how semaglutide’s effects go beyond weight loss—reducing inflammation and possibly encouraging new blood vessel growth—making it a game-changer for mobility.

References: Bonaca MP, Catarig AM, Houlind K, Ludvik B, Nordanstig J, Ramesh CK, Rasouli N, Sourij H, Videmark A, Verma S; STRIDE Trial Investigators. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet. 2025 May 3;405(10489):1580-1593. PMID: 40169145.

Thanks for watching and always remember: small tweaks lead to massive peaks!

–

Don’t forget to hit the subscribe button for more insightful content, and consider joining our YouTube Members Membership for exclusive content and early access to weekly videos. 

–

📺 Watch These Next:
▪️ Watch This Before Taking Mounjaro
▪️ From Ozempic to Mounjaro
▪️ Muscle Loss with Ozempic, Wegovy & Mounjaro
▪️ Managing Nausea from Ozempic, Wegovy and Trulicity!
▪️ Ozempic: Stomach Paralysis Update
▪️ How to Switch from Ozempic (or Wegovy) to Mounjaro
▪️ Ozempic Paralyzed My Stomach
▪️ How to Inject Mounjaro: step-by-step tutorial

–

🎯 Free Resources:
▪️ GLP-1/GIP Medication Info Sheet + 7-Day Food Journal
▪️ Total Daily Energy Expenditure (TDEE) Calculator – Find your optimal calorie intake

–
🛒 Recommended Products for Your Weight-Loss Journey:
▪️ Managing Constipation
▪️ Managing Heartburn
▪️ Protein Bars & Supplements
▪️ Activity Trackers & Scales

–

Live in Alberta? Come see me at my Pharmacist-led Obesity Clinic at Apothecare Pharmacy – http://apothecarerx.ca 

– 

Dr. Dan

Follow me on social media for regular updates – @TheOfficialDrDan

Subscribe to my newsletter for a heads-up on all new content.

Sharing is caring! Here’s the social, email, and even text link –
https://healthevolved.co/pad-semaglutide

If you need some coaching support on your weight management journey, you can book a consultation with me to see if you’d be a good fit for our program. 

Questions or comments? Please send them my way on our Contact Us page!